Evidence map›Paper›PMID 26989706›Full record

ArticleReports of biochemistry & molecular biology2012

Decreased levels of soluble Toll-like Receptor 2 in patients with asthma.

Mohsen Tehrani, Abdol-Reza Varasteh, Mohammad Reza Khakzad, Majid Mirsadraee, Mojtaba Sankian

Open access · greenAbstract read
In one paragraph

Article in Reports of biochemistry & molecular biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mohsen TehraniImmunobiochemistry lab, Immunology Research Center, Bu-Ali Research Institute, Mashhad, Iran.
Abdol-Reza VarastehImmunobiochemistry lab, Immunology Research Center, Bu-Ali Research Institute, Mashhad, Iran.
Mohammad Reza KhakzadZakaria Research Center, Azad University of Mashhad, Mashhad, Iran.
Majid MirsadraeeZakaria Research Center, Azad University of Mashhad, Mashhad, Iran.
Mojtaba SankianImmunobiochemistry lab, Immunology Research Center, Bu-Ali Research Institute, Mashhad, Iran.
Mashhad University of Medical Sciences · IRIslamic Azad University, Mashhad · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently, reports have indicated a role for the membrane form of Toll-like Receptor 2 (TLR2) in asthma pathogenesis. In this study we examined soluble TLR2 levels in serum and sputum of asthmatic and healthy subjects.

methodsSerum and sputum samples were obtained from 33 asthmatic and 19 healthy subjects. The asthmatics were classified into four groups according to the Global Initiative for Asthma. A sandwich ELISA was developed to measure soluble TLR2 (sTLR2) in serum and sputum. TLR2 mRNA expression was determined by semi-quantitative RT-PCR of all sputum samples.

resultsThe mean sTLR2 levels from serum and sputum of asthmatics were significantly lower than those from healthy subjects. Moreover, sTLR2 concentration decreased concomitantly with asthma severity. The differences observed, however, were not statistically significant. TLR2/GAPDH mRNA of sputum leukocytes was also significantly lower in asthmatics than in healthy subjects.

conclusionThis study demonstrated for the first time thatsTLR2 levels are lower in serum and sputum samples from asthmatic than from healthy subjects, and this could be an indicator of TLR2 expression. We also found that sTLR2 concentration in serum decreased concomitantly with an increase of asthma severity clinical score .

Indexed as

AsthmaExpressionSoluble Toll-like receptorTLR2 mRNA

Identifiers

PMID26989706
PMCPMC4757078
OpenAlexW2188569268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.